MannKind (MNKD) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Savara (SVRA) has outperformed MannKind (MNKD) over the past year, gaining 39.2% versus a loss of 37.1%. Over five years, SVRA leads with a +274.4% price change compared with -32.8% for MNKD. MannKind is the larger company by market cap ($1.06 billion vs $1.01 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNKD | SVRA |
|---|---|---|
| Share price | $3.29 | $4.92 |
| Market cap | $1.06B | $1.01B |
| 1-day change | -3.80% | +1.86% |
| YTD return | -39.68% | -19.90% |
| 1-year return | -37.13% | +39.19% |
| 5-year return | -32.81% | +274.42% |
| Forward P/E | 25.80 | — |
| EPS (TTM) | $-0.14 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.51 | $7.01 |
| 52-week low | $2.23 | $3.35 |
| Distance from 52-week high | -49.46% | -29.76% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +138.30% | +124.80% |
| Average volume | 4.50M | 1.83M |
| Shares outstanding | 321.54M | 205.46M |
| Employees | 591 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SVRA has outperformed MNKD by 76.3 percentage points over the past year.
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
MNKD vs SVRA FAQ
Which is bigger, MannKind or Savara?
MannKind (MNKD) is larger, with a market capitalization of $1.06B compared with $1.01B for Savara (SVRA).
Which stock has performed better over the past year, MNKD or SVRA?
SVRA returned +39.19% over the past 12 months, compared with -37.13% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are MannKind and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.